Representatives from Genea Biocells recently attended the International Dystrophia Myotonica Consortia (IDMC) held in San Francisco, CA. This meeting brought together the myotonic dystrophy (DM) research community including scientists, physicians, and health care professionals focused on clinical and scientific research. The meeting highlighted both DM1 and DM2, their molecular underpinnings, and the various manifestations of the disease including muscle weakness and wasting, cardiac dysfunction, intellectual disability, and developmental delays. In addition, the meeting highlighted clinically successful therapeutics for other neuromuscular diseases, e.g. Spinal Muscular Atrophy and Duchenne Muscular Dystrophy, from which the DM research community could draw upon in future DM clinical trials. The conference facilitated opportunities for the exchange of ideas and dialogue to progress the understanding of and development of targeted treatments for DM. For more information on the research Genea Biocells is engaged in please visit our site www.geneabiocells.com.
Please follow and like us: